KEY FINDINGS
The global DNA sequencing market growth is estimated to progress at a CAGR of 17.05% during the forecast period, 2021-2028. The market growth drivers include prevailing cancer cases, genome mapping programs implementation, increasing need for DNA sequencing in animals & plant reproduction, liquid biopsy applications, and growing R&D in DNA sequencing.
MARKET INSIGHTS
DNA sequencing helps in determining the nucleotide sequence of deoxyribonucleic acid (DNA). It has caused altering impacts in the genomics and molecular biology sectors. Genome mapping programs are on the rise globally. They increase awareness about NGS (Next-Generation Sequencing) and collect real-time sequences. They are also genetic data repositories for the world population. According to a December 2019 article, the GenomeAsia 100K consortium analyzed the genomes of 1739 people. It represented the vast genetic diversity coverage in Asia. It was launched in 2016 to understand the genome diversity of Asian ethnicities. Hosted by Nanyang Technological University, it is a non-profit consortium. At the same time, the market growth restraining factors include social & ethical issues, bioinformatics limitations, lack of skilled professionals, and accuracy concerns in diagnostic testing.
REGIONAL INSIGHTS
The geographical segmentation for the growth assessment of the global DNA sequencing market includes North America, Asia-Pacific, Europe, and Rest of World. With continuous technological innovations and the growing demand for drug discovery, Asia-Pacific is set to project the highest CAGR by 2028.
COMPETITIVE INSIGHTS
The strong competitive rivalry in the market is accredited to the price competition, innovations, and increasing adoption of new technologies. Bio-Rad Laboratories Inc, Asuragen Inc, BGI Genomics, Adaptive Biotechnologies Inc, Agilent Technologies Inc, etc., are among the market’s prominent players.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING NEED FOR DNA SEQUENCING IN ANIMALS & PLANT REPRODUCTION
3.1.2. TECHNOLOGICAL DEVELOPMENTS
3.1.3. GROWING RESEARCH AND DEVELOPMENT IN DNA SEQUENCING
3.1.4. PREVALENCE OF CANCER CASES
3.1.5. USAGE OF LIQUID BIOPSY APPLICATIONS
3.1.6. IMPLEMENTATION OF GENOME MAPPING PROGRAMS
3.2. KEY RESTRAINTS
3.2.1. ACCURACY AND STANDARDIZATION CONCERNS IN DIAGNOSTIC TESTING
3.2.2. LACK OF SKILLED PROFESSIONALS IN EMERGING ECONOMIES
3.2.3. LIMITATIONS IN BIOINFORMATICS
3.2.4. SOCIAL AND ETHICAL ISSUES
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DNA SEQUENCING MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
5. MARKET BY TECHNOLOGY
5.1. SEQUENCING BY SYNTHESIS
5.2. ION SEMICONDUCTOR SEQUENCING
5.3. CHAIN TERMINATION SEQUENCING
5.4. PYROSEQUENCING
5.5. SEQUENCING BY LIGATION (SBL)
5.6. SINGLE-MOLECULE REAL-TIME SEQUENCING (SMRT)
5.7. NANOPORE SEQUENCING
5.8. OTHER TECHNOLOGIES
6. MARKET BY APPLICATION
6.1. BIOMARKER DISCOVERY
6.2. DIAGNOSTICS
6.3. REPRODUCTIVE HEALTH
6.4. PERSONALIZED MEDICINE
6.5. DRUG DISCOVERY
6.6. AGRICULTURE & ANIMAL RESEARCH
6.7. FORENSICS
6.8. OTHER APPLICATIONS
7. MARKET BY PRODUCT
7.1. INSTRUMENTS & CONSUMABLES
7.1.1. INSTRUMENTS & CONSUMABLES TYPE
7.1.1.1. CONSUMABLES
7.1.1.2. INSTRUMENTS
7.1.2. INSTRUMENTS & CONSUMABLES PLATFORM
7.1.2.1. NGS (NEXT GENERATION SEQUENCING)
7.1.2.1.1. RNA SEQUENCING
7.1.2.1.2. TARGETED RESEQUENCING
7.1.2.1.3. WHOLE-EXOME SEQUENCING
7.1.2.1.4. WHOLE-GENOME SEQUENCING
7.1.2.1.5. CHIP SEQUENCING
7.1.2.1.6. DE NOVO SEQUENCING
7.1.2.1.7. METHYL SEQUENCING
7.1.2.2. SANGER
7.2. SEQUENCING SERVICES
7.3. BIOINFORMATICS
8. MARKET BY END-USER
8.1. RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
8.2. PHARMACEUTICAL
8.3. BIOTECHNOLOGY COMPANIES
8.4. HOSPITALS & CLINICS
8.5. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.2. CANADA
9.2. EUROPE
9.2.1. MARKET SIZE & ESTIMATES
9.2.2. KEY GROWTH ENABLERS
9.2.3. KEY CHALLENGE
9.2.4. KEY PLAYERS
9.2.5. COUNTRY ANALYSIS
9.2.5.1. GERMANY
9.2.5.2. FRANCE
9.2.5.3. UNITED KINGDOM
9.2.5.4. ITALY
9.2.5.5. RUSSIA
9.2.5.6. BELGIUM
9.2.5.7. POLAND
9.2.5.8. REST OF EUROPE
9.3. ASIA-PACIFIC
9.3.1. MARKET SIZE & ESTIMATES
9.3.2. KEY GROWTH ENABLERS
9.3.3. KEY CHALLENGE
9.3.4. KEY PLAYERS
9.3.5. COUNTRY ANALYSIS
9.3.5.1. CHINA
9.3.5.2. JAPAN
9.3.5.3. INDIA
9.3.5.4. AUSTRALIA & NEW ZEALAND
9.3.5.5. SOUTH KOREA
9.3.5.6. THAILAND
9.3.5.7. INDONESIA
9.3.5.8. VIETNAM
9.3.5.9. REST OF ASIA-PACIFIC
9.4. REST OF WORLD
9.4.1. MARKET SIZE & ESTIMATES
9.4.2. KEY GROWTH ENABLERS
9.4.3. KEY CHALLENGE
9.4.4. KEY PLAYERS
9.4.5. REGIONAL ANALYSIS
9.4.5.1. LATIN AMERICA
9.4.5.2. MIDDLE EAST & AFRICA
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ADAPTIVE BIOTECHNOLOGIES INC
10.2.2. AGILENT TECHNOLOGIES INC
10.2.3. ASURAGEN INC
10.2.4. BGI GENOMICS
10.2.5. BIO-RAD LABORATORIES INC
10.2.6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
10.2.7. EUROFINS SCIENTIFIC
10.2.8. F. HOFFMANN-LA ROCHE
10.2.9. ILLUMINA INC
10.2.10. MERCK KGAA
10.2.11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
10.2.12. PERKINELMER INC
10.2.13. SIEMENS HEALTHINEERS AG
10.2.14. SPIRAL GENETICS INC
10.2.15. THERMO FISHER SCIENTIFIC INC
10.2.16. UBIQUITY GENOMICS INC
1. ADAPTIVE BIOTECHNOLOGIES INC
2. AGILENT TECHNOLOGIES INC
3. ASURAGEN INC
4. BGI GENOMICS
5. BIO-RAD LABORATORIES INC
6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
7. EUROFINS SCIENTIFIC
8. F. HOFFMANN-LA ROCHE
9. ILLUMINA INC
10. MERCK KGAA
11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
12. PERKINELMER INC
13. SIEMENS HEALTHINEERS AG
14. SPIRAL GENETICS INC
15. THERMO FISHER SCIENTIFIC INC
16. UBIQUITY GENOMICS INC
